Bio-Rad Laboratories Long Term Debt

Bio-Rad Laboratories posts a long-term debt of $140M as of March 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bio-Rad Laboratories's long-term debt was $0. The latest reading is $140M (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Bio-Rad Laboratories's financial statement story. At $140M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BIO's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bio-Rad Laboratories's other metric pages and overview cover the third.

Judging Bio-Rad Laboratories against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $140M here, then scan peer and history charts to see if the gap is persistent.